PF-08049820 / Pfizer - LARVOL DELTA

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=69 | Recruiting | Sponsor: Pfizer | N=53 ➔ 69

Enrollment change

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Pfizer

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Pfizer PF-08049820 initiates Phase I clinical trial for moderate to severe atopic dermatitis [Google translation] (Sina Corp) - "The clinical trial registration number is CTR20253768, and the first public information date is September 17, 2025...The primary endpoints of this trial include plasma PF-08049820 PK parameters: Cmax and AUCinf (if data permit, otherwise AUClast); secondary endpoints include treatment-emergent AEs....Currently, the experiment is in progress (not yet recruited), with a target enrollment of 18 participants."

Trial status • Atopic Dermatitis

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Pfizer

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: Pfizer | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: Pfizer | N=21 ➔ 53

Enrollment change

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open